The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer
JAMA Oncol
.
2019 Oct 1;5(10):1511-1512.
doi: 10.1001/jamaoncol.2019.2985.
Authors
Kanwal Raghav
1
,
John H Strickler
2
Affiliations
1
The University of Texas MD Anderson Cancer Center, Houston.
2
Duke University Medical Center, Durham, North Carolina.
PMID:
31415062
DOI:
10.1001/jamaoncol.2019.2985
No abstract available